Therapy News and Research

RSS

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Investigators from Massachusetts General Hospital and the Harvard Stem Cell Institute have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival.

27 Apr 2015

Ikonopedia's breast imaging reporting tools, MQSA management system selected for use by BelleBridge

Ikonopedia announced today that its breast imaging reporting tools and MQSA management system have been selected for use by BelleBridge, which provides telemedicine services for interpretations of breast screening and diagnostic examinations.

27 Apr 2015

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.

25 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Record number of abstracts submitted to Heart Failure 2015

A record number of abstracts have been submitted to the world's leading heart failure congress, promising more original science than ever before.

25 Apr 2015

Multicentre study provides hope for malaria therapy with just one dose

Approximately 584,000 people worldwide die of malaria each year. The epidemic strongly associated with poverty claims most of its victims in Africa, where it particularly affects the weakest, children and pregnant women. Current therapies have to be taken over several days to be effective against malaria.

25 Apr 2015

iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft Axxent Electronic Brachytherapy (eBx) System in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Utilising trusted and clinically proven low energy photons, in a dedicated treatment system. Photoelectric Therapy provides a pain free, non-surgical alternative for the treatment of non-melanoma skin cancer, especially those found in sensitive areas of the head and neck...

24 Apr 2015

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology.

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

UTMB study highlights current use of oxygen therapy in patents with COPD

A new study about the use of oxygen to treat chronic obstructive pulmonary disease from The University of Texas Medical Branch at Galveston found that the majority of patients receiving oxygen therapy were low-income, non-Hispanic white females about 75 years old with two or more other health conditions.

24 Apr 2015

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.

24 Apr 2015

Therapy News and Research

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Ikonopedia's breast imaging reporting tools, MQSA management system selected for use by BelleBridge

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Record number of abstracts submitted to Heart Failure 2015

Multicentre study provides hope for malaria therapy with just one dose

iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Study identifies BLU-554 as potential treatment option for HCC patients

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Alternative treatment options for uterine fibroids

UTMB study highlights current use of oxygen therapy in patents with COPD

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News